Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis

Everest Medicines (HKG: 1952) announced the formal commercial launch of Etrasimod, with the first prescription issued on the same day, marking the China market entry of the next-generation sphingosine-1-phosphate (S1P) receptor modulator. The drug, which received NMPA approval in February 2026 for moderately to severely active ulcerative colitis (UC), represents Everest’s first commercialized asset from its 2017 Arena Pharmaceuticals partnership, positioning the company to capture share of China’s rapidly expanding inflammatory bowel disease market.

Contents

Launch Milestone
Product Profile & Differentiation
Market Context & Commercial Strategy
Competitive Landscape
Forward-Looking Priorities

- Advertisement -

Launch Milestone

Element	Detail
Product	Etrasimod
Drug Class	Next-generation S1P receptor modulator (S1P1,4,5)
Developer	Arena Pharmaceuticals (acquired by Pfizer 2022)
China Rights	Everest Medicines – exclusive development, manufacturing, commercialization in Greater China and South Korea (2017 agreement)
NMPA Approval	February 2026
Indication	Moderately to severely active ulcerative colitis (inadequate response/intolerance to conventional therapy or biologics)
Launch Date	9 Mar 2026 (first prescription issued)
Sponsor	Everest Medicines (HKG: 1952)

Product Profile & Differentiation

Attribute	Etrasimod Specification
Target	Sphingosine-1-phosphate receptors 1, 4, and 5 (S1P1,4,5)
Mechanism	Sequesters lymphocytes in lymph nodes; reduces circulating autoreactive T-cells in gut mucosa
Pharmacological Design	Optimized selectivity vs. first-gen S1P modulators
Route	Oral once-daily
Differentiation	No requirement for first-dose cardiac monitoring (vs. fingolimod); rapid onset; improved lymphocyte recovery profile

Competitive Positioning vs. Standard of Care:

Parameter	Etrasimod	Conventional Therapy	Biologics (anti-TNF, vedolizumab)
Mechanism	S1P1,4,5 modulation	5-ASA, immunosuppressants	Systemic/integrin-targeted biologics
Administration	Oral, no infusion	Oral/topical	IV/SC injection
Safety Profile	No cardiac monitoring; manageable lymphopenia	GI intolerance, nephrotoxicity	Immunosuppression, infusion reactions
Positioning	Bio-naïve and bio-failure patients	First-line maintenance	Moderate-severe, hospitalization risk

Market Context & Commercial Strategy

Factor	Strategic Implication
China UC Market	400,000+ diagnosed patients; 10% annual growth; biologic penetration <15% vs. 40%+ in U.S./EU
Unmet Need	Significant patient population with inadequate response to 5-ASA or intolerance to anti-TNF therapy
Pricing Strategy	Expected NRDL negotiation 2026-2027; premium positioning justified by oral convenience vs. biologics
Pfizer Synergy	Global Arena acquisition validates etrasimod mechanism; Everest retains China commercial independence
Pipeline Expansion	Crohn’s disease Phase III ongoing; atopic dermatitis, alopecia areata potential indications

Competitive Landscape

Competitor	Product	Mechanism	China Status	Etrasimod Advantage
Novartis	Gilenya (fingolimod)	S1P1,2,3,4,5 (non-selective)	Approved (MS)	Selectivity reduces cardiac/bronchial adverse effects
BMS	Zeposia (ozanimod)	S1P1,5	Approved (UC) in U.S./EU; China pending	S1P4 engagement may enhance efficacy; first-mover China advantage
Pfizer	Velsipity (etrasimod)	S1P1,4,5	Approved (UC) U.S. 2023	Everest exclusive China rights; local manufacturing
Everest	Etrasimod	S1P1,4,5	Launched (UC)	Only next-gen S1P modulator approved in China for IBD

Forward-Looking Priorities

2026 Execution: Hospital formulary access; gastroenterologist education; patient identification in tertiary centers
NRDL Negotiation: 2026-2027 national reimbursement list inclusion critical for volume expansion
Crohn’s Expansion: Phase III data anticipated 2027; label extension doubles addressable IBD population
South Korea Launch: Parallel regulatory pathway; 2026-2027 commercialization anticipated

Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch performance, reimbursement negotiations, and pipeline expansion for etrasimod in Greater China. Actual results may differ due to competitive dynamics with biologics, pricing regulations, and manufacturing scale-up.-Fineline Info & Tech

Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis

Launch Milestone

Product Profile & Differentiation

Market Context & Commercial Strategy

Competitive Landscape

Forward-Looking Priorities

You May also Like

Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha

NMPA Approves Kyowa Hakko Kirin’s Mogamulizumab for Sezary Syndrome and Mycosis Fungoides

China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials

Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies

About Company